{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-002037","form_type":"8-K","ticker":"REGN","cik":"0000872589","company_name":"REGENERON PHARMACEUTICALS, INC.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.096751+00:00","generated_at":"2026-06-07T02:46:20.826412+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Regeneron reports preliminary Q4 U.S. EYLEA HD sales of $123M; IPR&D charge of $30M","bullets":["Preliminary Q4 2023 U.S. net product sales: EYLEA HD $123M, EYLEA $1.34B, combined $1.46B.","Acquired IPR&D charge of $30M pre-tax from Intellia collaboration extension, reducing GAAP and non-GAAP EPS by ~$0.21.","Dupixent global net sales through 9M 2023: ~$8.4B, up 34% YoY; pivotal COPD data supports 2024 launch potential.","EYLEA HD FDA-approved August 2023 for wAMD, DME, DR; ~2/3 of eligible lives covered, permanent J-code expected April 1, 2024.","Oncology pipeline: BLAs submitted for odronextamab (B-NHL) and linvoseltamab (MM); potential for up to three FDA approvals by end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-002037","json":"https://secwatch.observer/filing/0001104659-24-002037.json","markdown":"https://secwatch.observer/filing/0001104659-24-002037.md","text":"https://secwatch.observer/filing/0001104659-24-002037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872589/000110465924002037/0001104659-24-002037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872589/000110465924002037/tm242296d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:46:20.826412+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"85cd3ac0654d8f37d44a8b8969754c380c88d292","claim":"REGENERON PHARMACEUTICALS, INC. reported fourth quarter 2023 results: EPS $0.21.","evidence_excerpt":"the Company’s preliminary (unaudited) fourth quarter 2023 U.S. net product sales of EYLEA ® HD (aflibercept) Injection 8 mg of approximately $123 million and the Company’s preliminary (unaudited) fourth quarter 2023 U.S. net product sales of EYLEA ® (aflibercept) Injection of approximately $1.34 billion","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/872589/000110465924002037/0001104659-24-002037-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter 2023"},{"label":"EPS","value":"$0.21"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}